SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) --
Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the successful completion of an open-label Phase 3b clinical trial that evaluated OTIPRIO® (ciprofloxacin otic suspension) in 501 pediatric patients with a history of otitis media requiring tympanostomy tube placement (TTP) surgery. The Phase 3b trial was designed primarily to evaluate OTIPRIO in a broader pediatric patient population than the previous Phase 3 trials by including patients undergoing common concurrent surgeries and patients without bilateral effusion on the day of surgery. The study also collected patient insurance information to evaluate differences in outcomes for patients with Medicaid versus commercial insurance, and assessed caregiver burden via a questionnaire.
Summary results of the Phase 3b OTIPRIO trial are as follows:
- The incidence of post-operative otorrhea was lower in patients without bilateral effusion and also lower in patients undergoing a concurrent adenoidectomy when compared to patients with bilateral effusion and those undergoing TTP surgery alone, respectively.
- The incidence of otorrhea was similar for patients covered by commercial insurance and Medicaid over the eight-week follow-up period.
- The incidence of otorrhea reported through Day 15 was comparable to the proportion of patients with treatment failure due to otorrhea through Day 15 in the OTIPRIO treated groups of the Phase 3 trials.
- OTIPRIO was well tolerated and the adverse event profile was generally comparable to the previous Phase 3 trials.
- The caregiver survey indicated increased discomfort, lack of confidence, and degree of non-compliance when ear drops were required.
Full results from the trial will be presented at an upcoming medical conference.
“This study provides important information regarding the use of OTIPRIO in a patient population that reflects real-world clinical practice and further supports the utility of OTIPRIO administered as a single intraoperative dose by the physician,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Furthermore, the benefit of assured compliance with OTIPRIO is highlighted by the increased caregiver burden associated with patients who required antibiotic ear drops, as well as by the similar outcomes measured regardless of the patient's insurance status. This last point is particularly noteworthy given the well-documented observation in other conditions, such as pediatric asthma, that medication adherence is lower and clinical outcomes are generally worse in the Medicaid patient population."
The open-label Phase 3b clinical trial enrolled a total of 501 pediatric patients at multiple centers throughout the United States. Patients received a single administration of OTIPRIO in each ear during TTP surgery. The clinical activity of OTIPRIO was measured through assessment of the presence of otorrhea, or drainage from the tube. Safety was assessed through adverse event reporting and otoscopic examinations over a two-month follow-up period. This trial also assessed caregiver burden associated with multi-dose, multi-day antibiotic ear drops in the subset of study patients who required ear drops in the post-operative follow-up period.
OTIPRIO (ciprofloxacin otic suspension) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. OTIPRIO is administered by a physician as a single 0.1 mL (6 mg) intratympanic administration into each affected ear, following suctioning of the middle ear effusion. The thermosensitive suspension exists as a liquid at or below room temperature and gels when warmed. In two Phase 3 trials, a single intraoperative administration of OTIPRIO demonstrated a statistically significant reduction in the cumulative proportion of study treatment failures compared to tubes alone (p-value <0.001).
Important Safety Information for OTIPRIO
Contraindications: OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.
Warnings and Precautions - Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.
Adverse Reactions: Adverse reactions (incidence at least 3%) that occurred in two Phase 3 trials with OTIPRIO vs sham were: nasopharyngitis (5% vs 4%), irritability (5% vs 3%), and rhinorrhea (3% vs 2%).
Use in Specific Populations - Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.
Full prescribing information can be found at www.OTIPRIO.com.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, and commercial launch commenced in March 2016. OTO-104 is a steroid in development for the treatment of Ménière's disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are underway, with results expected during the second half of 2017. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that is in a Phase 1 clinical safety trial. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician. For additional information please visit www.otonomy.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Otonomy. Forward-looking statements in this press release include, but are not limited to, the timing of results for the two OTO-104 Phase 3 clinical trials in Ménière's disease. Otonomy's expectations regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Otonomy's limited operating history and its expectation that it will incur significant losses for the foreseeable future; Otonomy's ability to obtain additional financing; Otonomy's dependence on the commercial success of OTIPRIO and the regulatory success and advancement of additional product candidates, such as OTO-104 and OTO-311, and label expansion indications for OTIPRIO; the uncertainties inherent in the clinical drug development process, including, without limitation, Otonomy's ability to adequately demonstrate the safety and efficacy of its product candidates, the preclinical and clinical results for its product candidates, which may not support further development, and challenges related to patient enrollment in clinical trials; Otonomy's ability to obtain regulatory approval for its product candidates; side effects or adverse events associated with Otonomy's product candidates; competition in the biopharmaceutical industry; Otonomy's dependence on third parties to conduct preclinical studies and clinical trials; the timing and outcome of hospital pharmacy and therapeutics reviews and other facility reviews; the impact of coverage and reimbursement decisions by third-party payors on the pricing and market acceptance of OTIPRIO; Otonomy's dependence on third parties for the manufacture of OTIPRIO and product candidates; Otonomy's dependence on a small number of suppliers for raw materials; Otonomy's ability to protect its intellectual property related to OTIPRIO and its product candidates in the United States and throughout the world; expectations regarding potential market size, opportunity and growth; Otonomy's ability to manage operating expenses; implementation of Otonomy's business model and strategic plans for its business, products and technology; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in Otonomy's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 4, 2016, and Otonomy's future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.
Contacts: Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Senior Vice President 619.849.5377 email@example.com Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 firstname.lastname@example.org